In a randomized double-blind placebo controlled crossover study 19 volunteers consumed 3 doses of resVida (30 mg 90 mg 270 mg) and a placebo at weekly intervals. Flow-mediated dilatation (FMD) of the brachial artery was measured one hour after ingestion of each treatment and was significantly increased at all 3 doses relative to placebo. 30 mg of resVida demonstrated 2.5% greater increase in FMD relative to placebo.